Aclaris reports Q1 net loss $16.9M, down 40% YoY; advances ATI-2138 into Phase 2a for AD

Aclaris Therapeutics, Inc.

2024-Q1 EPS reported -$0.24 revenue$2,398,000

Net loss narrowed to $16.9M from $28.2M YoY; total revenue $2.4M, flat.
Cash and marketable securities $161.4M at March 31, 2024; expects lower quarterly cash burn ahead.
Progressing ATI-2138 (ITK/JAK3 inhibitor) into Phase 2a proof-of-concept trial for moderate-to-severe atopic dermatitis.
Seeking global development partner for lepzacitinib (topical JAK 1/3 inhibitor) after positive Phase 2b AD data.
R&D expenses fell to $9.8M from $22.6M, driven by wind-down of programs and workforce reduction.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aclaris Therapeutics, Inc. reported first quarter of 2024 results: revenue $2.4 million, net income Net loss was $16.9 million.

Period: first quarter of 2024
Revenue: $2.4 million
Net income: Net loss was $16.9 million
Result: reported results

Exact text from the filing

Financial Results First Quarter 2024 ● Net loss was $16.9 million for the first quarter of 2024 compared to $28.2 million for the first quarter of 2023. ● Total revenue was $2.4 million for the first quarter of 2024 compared to $2.5 million for the first quarter of 2023. The decrease was primarily driven by lower contract research revenue during the three months

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Aclaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-007055

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.